Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Third-party virus-specific cytotoxic T-cell therapy for viral reactivation after allogeneic stem cell transplant
ACTRN12613000603718Phase 2Recruiting
- Sponsor
- Western Sydney Local Health District
- Start
- Feb 2013
- Modality
- Vaccines & Immunotherapeutics, Cell Therapies
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of Virus-specific Cytotoxic T-lymphocytes in cytomegalovirus disease (CMV), Epstein-Barr virus infection, adenoviral infection and 1 more, sponsored by Western Sydney Local Health District. Primary endpoint: Safety. Started Feb 2013; status: recruiting.
02
Drugs
Virus-specific Cytotoxic T-lymphocytes
03
Conditions
cytomegalovirus disease (CMV)Epstein-Barr virus infectionadenoviral infectionPost-Transplant Lymphoproliferative Disorder (PTLD)
Beyond the preview
Go deeper on ACTRN12613000603718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12613000603718.